Pentadecanoic acid (C15:0) is a 15-carbon odd-chain saturated fatty acid found naturally in full-fat dairy products and the fat of ruminant animals. Unlike the even-chain saturated fats that have long dominated nutrition debates, C15:0 has attracted growing scientific attention as a potential marker and possibly a mediator of cardiometabolic health. Because blood levels of C15:0 closely reflect dairy fat intake, it serves as a useful objective biomarker in large epidemiological studies.
Several prospective cohort studies and meta-analyses have found that higher circulating C15:0 levels are associated with lower rates of cardiovascular disease, heart attack, and hypertension. At the same time, a 2026 analysis in two major U.S. cohorts concluded that these associations are modest and without evidence of direct causality [11]. This article reviews what the research actually shows, what proposed mechanisms exist, and where the evidence still has meaningful gaps.
Key Takeaways
- Multiple large prospective studies and meta-analyses find that higher circulating C15:0 levels are consistently associated with lower cardiovascular disease risk [7] [5] [8].
- A rigorous 2026 analysis in the CARDIA and ARIC cohorts found the relationship between plasma C15:0 and cardiovascular health to be modest and without evidence of direct causality [11].
- Higher C15:0 is also inversely associated with hypertension in cross-sectional NHANES data, but cross-sectional studies cannot establish cause and effect [9].
- Proposed mechanisms including PPAR-alpha/delta agonism and cell membrane integration are biologically plausible but have not been confirmed in controlled cardiovascular intervention trials.
- C15:0 supplements appear well tolerated at studied doses of 100 to 300 mg per day, but no clinical trial has demonstrated that supplementation reduces cardiovascular disease risk.
What Is C15:0 and Why Does It Interest Researchers?
Pentadecanoic acid belongs to a family of odd-chain fatty acids that, unlike even-chain saturated fats, cannot be synthesized in substantial amounts by most human cells. A 2015 review of odd-chain fatty acid metabolism noted that C15:0 and its 17-carbon relative heptadecanoic acid (C17:0) enter several biochemical pathways and appear to have distinct physiological effects compared to even-chain saturated fatty acids [2].
Researchers at Epitracker have proposed that C15:0 may function as a partially essential fatty acid based on its ability to integrate into cell membranes and act as a partial agonist at PPAR-alpha and PPAR-delta receptors. These are nuclear receptors involved in fatty acid metabolism, inflammation, and glucose regulation. The researchers have also proposed that C15:0 may reduce ferroptosis (an iron-mediated form of cell death) and cellular senescence. These mechanisms are biologically plausible and have generated genuine scientific interest, but the classification of C15:0 as essential has not been formally adopted by regulatory bodies or mainstream nutrition science.
What Large Observational Studies Have Found
Much of the cardiovascular evidence for C15:0 comes from prospective cohort studies that measure circulating fatty acid levels at baseline and track participants for cardiovascular events over years. The EPIC-Norfolk study, a large UK prospective cohort, found that higher plasma phospholipid C15:0 levels were associated with lower incident coronary heart disease [1]. This study was influential in drawing attention to the possible role of odd-chain fatty acids in heart health.
A 2022 meta-analysis pooling data from multiple prospective studies found that circulating C15:0 and C17:0 were inversely associated with risk of cardiometabolic diseases including cardiovascular disease and type 2 diabetes [7]. A separate systematic review and meta-analysis focused on dairy fat biomarkers also found that higher C15:0 was associated with lower cardiovascular disease risk across multiple cohorts [5]. A 2017 review of milk fat biomarkers reached similar conclusions, noting consistent inverse associations between C15:0 levels and cardiometabolic disease outcomes in the literature [4].
A large 2025 analysis drawing on individual-level data from three major prospective cohorts, alongside an updated meta-analysis, found that circulating C15:0 was among the fatty acids associated with lower cardiovascular disease risk [8]. Taken together, the observational pattern pointing toward a potential protective association is consistent across multiple independent datasets and study populations.
C15:0, Blood Pressure, and Hypertension
Hypertension is a leading modifiable risk factor for cardiovascular disease, and a 2025 cross-sectional analysis using National Health and Nutrition Examination Survey (NHANES) data specifically examined the relationship between serum C15:0 levels and hypertension status. The study found that higher serum C15:0 was inversely associated with hypertension, meaning participants with higher C15:0 tended to have lower rates of high blood pressure [9]. The same inverse association was observed for C17:0.
This finding is consistent with the broader cardiovascular association literature. However, a cross-sectional design captures a single snapshot in time and cannot determine whether higher C15:0 directly reduces blood pressure risk, whether people with healthier diets overall simply happen to have higher C15:0, or whether other unmeasured factors explain both.
A Critical Check: Modest Associations and the Causality Problem
A 2026 study published in Frontiers in Nutrition examined plasma C15:0 in relation to cardiovascular health in the CARDIA and ARIC cohorts, two of the most carefully followed long-term cardiovascular studies in the United States. The authors concluded that plasma C15:0 was only modestly related to cardiovascular health outcomes and found no evidence of causality after applying rigorous analytical methods [11]. This is a meaningful constraint on more optimistic readings of the earlier observational data.
The confounding concern is real: because C15:0 levels in blood primarily reflect how much dairy fat a person eats, the apparent ‘protective’ association could partly reflect the broader diet quality or lifestyle factors that tend to accompany full-fat dairy consumption in studied populations. A 2025 narrative review of C15:0 and cardiovascular disease acknowledged both the consistent epidemiological associations and the unresolved questions around mechanism and causation [10]. A broader 2015 commentary also cautioned against treating saturated fatty acid research as settled, noting the complexity of the evidence base [3].
Proposed Biological Mechanisms With Cardiovascular Relevance
Several pathways have been proposed to explain how C15:0 might influence the cardiovascular system at a biological level. As a partial PPAR-alpha agonist, C15:0 could influence lipid metabolism and reduce systemic inflammation, both of which are directly relevant to atherosclerosis and cardiac risk. PPAR-delta activation has been linked in experimental research to improved insulin sensitivity and anti-inflammatory effects in vascular tissue. The integration of C15:0 into cell membranes may also alter membrane fluidity and affect downstream signaling relevant to vascular function.
A Chinese cohort study found that a dietary pattern characterized by higher biomarker levels of odd-chain fatty acids was associated with lower risk of both coronary artery disease and type 2 diabetes, suggesting that cardiovascular and metabolic effects may be interrelated [6]. These mechanistic pathways remain plausible hypotheses rather than confirmed explanations, and human intervention trials directly testing whether raising C15:0 through supplementation improves cardiovascular outcomes have not yet been published.
What This Means for C15:0 Supplementation
The evidence reviewed here is predominantly observational, tracking C15:0 levels that arise naturally from diet rather than from supplement use. Moving from the finding that ‘people with higher circulating C15:0 tend to have lower cardiovascular disease rates’ to the claim that ‘supplementing with C15:0 will reduce your cardiovascular risk’ requires causal evidence that does not yet exist.
Published research on C15:0 supplementation has generally used doses of 100 to 300 mg per day and has not reported serious adverse events, suggesting that the supplement is well tolerated in healthy adults at these levels. The FDA has not evaluated C15:0 for the treatment or prevention of any cardiovascular condition, and available supplement studies were not designed or powered to measure cardiovascular outcomes. Individuals with existing heart disease, hypertension, or who take lipid-modifying medications should speak with a physician before adding any fatty acid supplement to their routine.
🛒 Where to Buy Pentadecanoic Acid (C15:0)
- Epitracker Fatty15 C15:0 Fatty Acid SupplementLab-tested / studied
capsules, 100 mg C15:0 per capsule; 1 capsule/day starter, 2 capsules/day maintenance — Category creator; the only C15:0 supplement backed by the original Epitracker research team (Venn-Watson et al.); uses a patented, sustainably-sourced pure C15:0 ingredient; most expensive per-capsule but reference product for all comparisons - Double Wood Supplements Pentadecanoic Acid C15:0
capsules, 200 mg C15:0 per serving (2 capsules) — One of the first genericized C15:0 supplements; significantly lower price than Fatty15; no independent clinical trials on this specific product; good option for budget-conscious buyers who want to trial the fatty acid - Sports Research Pentadecanoic Acid C15:0
softgels, 100 mg C15:0 per softgel — Established supplement brand with strong Amazon presence; third-party tested; softgel form may aid fat-soluble absorption; competitively priced mid-tier option - BulkSupplements Pentadecanoic Acid Powder (C15:0)
powder, 100–300 mg per measured serving — Most economical option for higher-dose protocols or stackers; requires a milligram-accurate scale; no excipients or additives; not recommended for beginners unfamiliar with powder dosing
As an Amazon Associate we earn from qualifying purchases. Shilajit quality varies widely — always choose a product with a published third-party heavy-metal test (COA) before buying.
A Note on the Evidence
The cardiovascular evidence for C15:0 is largely observational and does not establish causality; the hypothesis that C15:0 is a partially essential fatty acid remains under active investigation and has not been adopted by regulatory nutrition bodies. People with heart disease, hypertension, or those taking lipid-modifying medications should consult a qualified healthcare provider before adding C15:0 supplements to their routine.
Frequently Asked Questions
What does the research say about C15:0 and coronary heart disease?
Prospective observational studies, including the EPIC-Norfolk cohort, have found inverse associations between circulating C15:0 levels and incident coronary heart disease [1]. A meta-analysis of prospective studies also found lower cardiometabolic disease risk with higher odd-chain fatty acid levels [7]. These are associations in observational data, not proof of a causal protective effect from raising C15:0 through supplementation.
Does C15:0 affect blood pressure?
A 2025 NHANES cross-sectional analysis found that higher serum C15:0 levels were inversely associated with hypertension, meaning participants with higher C15:0 tended to have lower rates of high blood pressure [9]. This is consistent with the broader cardiovascular association data, but a cross-sectional design cannot determine whether C15:0 directly influences blood pressure or whether both reflect a healthier dietary pattern overall.
How is C15:0 different from other saturated fats in terms of cardiovascular risk?
C15:0 is an odd-chain saturated fatty acid, which places it in a biochemically distinct category from more studied even-chain saturated fats like palmitic acid. A 2015 review of odd-chain fatty acid metabolism noted that C15:0 enters different metabolic pathways and that its associations with cardiometabolic outcomes are consistently more favorable than those of even-chain saturates [2]. This distinction is one reason researchers have singled it out for closer study.
Is there evidence that C15:0 supplements reduce cardiovascular risk?
No published randomized controlled trial has demonstrated that C15:0 supplementation reduces cardiovascular events or risk markers. A 2026 analysis specifically found that plasma C15:0 associations with cardiovascular health were modest and without evidence of causality [11]. The observational evidence is interesting but cannot be directly translated into a supplementation recommendation for heart health.
Could the cardiovascular association just reflect healthier dairy habits rather than C15:0 itself?
This is a genuine interpretive challenge. Because C15:0 blood levels mainly reflect dairy fat intake, the observed inverse associations with cardiovascular disease could partly be driven by confounding variables related to diet quality or lifestyle rather than the fatty acid itself. A 2017 review of milk fat biomarkers and cardiometabolic disease acknowledged this limitation [4], and a 2025 narrative review also noted that the causal picture remains unresolved [10].
Are C15:0 supplements safe to take?
Published research on C15:0 supplementation at doses of 100 to 300 mg per day has not reported serious adverse events, suggesting the supplement is generally well tolerated in healthy adults at these levels. However, long-term safety data are limited, the FDA has not evaluated C15:0 for any health condition, and people with cardiovascular disease, hypertension, or who take medications that affect lipid metabolism should consult a physician before supplementing. This is informational content and not medical advice.
References
- Khaw KT et al. Plasma phospholipid fatty acid concentration and incident coronary heart disease in men and women: the EPIC-Norfolk prospective study. PLoS medicine (2012). PMID 22802735
- Jenkins B et al. A review of odd-chain fatty acid metabolism and the role of pentadecanoic Acid (c15:0) and heptadecanoic Acid (c17:0) in health and disease. Molecules (Basel, Switzerland) (2015). PMID 25647578
- Dawczynski C et al. Saturated fatty acids are not off the hook. Nutrition, metabolism, and cardiovascular diseases : NMCD (2015). PMID 26626084
- Risérus U et al. Milk fat biomarkers and cardiometabolic disease. Current opinion in lipidology (2017). PMID 27906713
- Liang J et al. Biomarkers of dairy fat intake and risk of cardiovascular disease: A systematic review and meta analysis of prospective studies. Critical reviews in food science and nutrition (2018). PMID 28001085
- Seah JYH et al. A Dietary Pattern Derived from Reduced Rank Regression and Fatty Acid Biomarkers Is Associated with Lower Risk of Type 2 Diabetes and Coronary Artery Disease in Chinese Adults. The Journal of nutrition (2019). PMID 31386157
- Li Z et al. Saturated fatty acid biomarkers and risk of cardiometabolic diseases: A meta-analysis of prospective studies. Frontiers in nutrition (2022). PMID 36046138
- Shi F et al. Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis. European journal of preventive cardiology (2025). PMID 39365172
- Chen T et al. Associations between serum pentadecanoic acid (C15:0) and heptadecanoic acid (C17:0) levels and hypertension: a cross-sectional analysis of NHANES data. Lipids in health and disease (2025). PMID 40542410
- Mercola J et al. Pentadecanoic acid (C15:0) and cardiovascular disease: A narrative review. World journal of cardiology (2025). PMID 41480001
- Steffen BT et al. Plasma pentadecanoic acid is modestly related to cardiovascular health in CARDIA and ARIC cohorts: observational associations without evidence of causality. Frontiers in nutrition (2026). PMID 41743064
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.